vs
Medpace Holdings, Inc.（MEDP）与罗布乐思（RBLX）财务数据对比。点击上方公司名可切换其他公司
罗布乐思的季度营收约是Medpace Holdings, Inc.的2.0倍（$1.4B vs $708.5M），Medpace Holdings, Inc.净利率更高（19.1% vs -22.3%，领先41.4%），罗布乐思同比增速更快（43.2% vs 32.0%），罗布乐思自由现金流更多（$308.6M vs $188.1M），过去两年罗布乐思的营收复合增速更高（32.9% vs 17.7%）
Medpace Holdings, Inc.是总部位于美国俄亥俄州辛辛那提的全球性临床研究机构（CRO），现有员工约6000人。公司采用全服务运营模式，可提供全球中心实验室、影像核心实验室、生物分析实验室服务，且在总部临床研究园区内设有I期临床试验单元。
罗布乐思（Roblox Corporation）是总部位于美国加利福尼亚州圣马特奥的游戏企业，由大卫·巴斯祖奇与埃里克·卡塞尔于2004年共同创立。公司核心产品为同名线上游戏创作平台Roblox，于2006年正式上线，截至2024年12月底全球员工规模已超2400人。
MEDP vs RBLX — 直观对比
营收规模更大
RBLX
是对方的2.0倍
$708.5M
营收增速更快
RBLX
高出11.2%
32.0%
净利率更高
MEDP
高出41.4%
-22.3%
自由现金流更多
RBLX
多$120.5M
$188.1M
两年增速更快
RBLX
近两年复合增速
17.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $708.5M | $1.4B |
| 净利润 | $135.1M | $-316.0M |
| 毛利率 | — | 77.7% |
| 营业利润率 | 21.6% | -25.3% |
| 净利率 | 19.1% | -22.3% |
| 营收同比 | 32.0% | 43.2% |
| 净利润同比 | 15.5% | -43.9% |
| 每股收益（稀释后） | $4.65 | $-0.44 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MEDPRBLX
| Q4 25 | $708.5M | $1.4B | ||
| Q3 25 | $659.9M | $1.4B | ||
| Q2 25 | $603.3M | $1.1B | ||
| Q1 25 | $558.6M | $1.0B | ||
| Q4 24 | $536.6M | $988.2M | ||
| Q3 24 | $533.3M | $919.0M | ||
| Q2 24 | $528.1M | $893.5M | ||
| Q1 24 | $511.0M | $801.3M |
净利润MEDPRBLX
| Q4 25 | $135.1M | $-316.0M | ||
| Q3 25 | $111.1M | $-255.6M | ||
| Q2 25 | $90.3M | $-278.4M | ||
| Q1 25 | $114.6M | $-215.1M | ||
| Q4 24 | $117.0M | $-219.6M | ||
| Q3 24 | $96.4M | $-239.3M | ||
| Q2 24 | $88.4M | $-205.9M | ||
| Q1 24 | $102.6M | $-270.6M |
毛利率MEDPRBLX
| Q4 25 | — | 77.7% | ||
| Q3 25 | — | 78.2% | ||
| Q2 25 | — | 78.2% | ||
| Q1 25 | — | 78.3% | ||
| Q4 24 | — | 77.9% | ||
| Q3 24 | — | 77.7% | ||
| Q2 24 | — | 77.8% | ||
| Q1 24 | — | 77.7% |
营业利润率MEDPRBLX
| Q4 25 | 21.6% | -25.3% | ||
| Q3 25 | 21.5% | -21.8% | ||
| Q2 25 | 20.9% | -29.8% | ||
| Q1 25 | 20.3% | -24.6% | ||
| Q4 24 | 23.4% | -24.7% | ||
| Q3 24 | 21.1% | -30.4% | ||
| Q2 24 | 19.9% | -26.6% | ||
| Q1 24 | 20.4% | -37.7% |
净利率MEDPRBLX
| Q4 25 | 19.1% | -22.3% | ||
| Q3 25 | 16.8% | -18.8% | ||
| Q2 25 | 15.0% | -25.8% | ||
| Q1 25 | 20.5% | -20.8% | ||
| Q4 24 | 21.8% | -22.2% | ||
| Q3 24 | 18.1% | -26.0% | ||
| Q2 24 | 16.7% | -23.0% | ||
| Q1 24 | 20.1% | -33.8% |
每股收益（稀释后）MEDPRBLX
| Q4 25 | $4.65 | $-0.44 | ||
| Q3 25 | $3.86 | $-0.37 | ||
| Q2 25 | $3.10 | $-0.41 | ||
| Q1 25 | $3.67 | $-0.32 | ||
| Q4 24 | $3.67 | $-0.32 | ||
| Q3 24 | $3.01 | $-0.37 | ||
| Q2 24 | $2.75 | $-0.32 | ||
| Q1 24 | $3.20 | $-0.43 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $497.0M | $3.1B |
| 总债务越低越好 | — | $1.2B |
| 股东权益账面价值 | $459.1M | $394.5M |
| 总资产 | $2.0B | $9.6B |
| 负债/权益比越低杠杆越低 | — | 2.98× |
8季度趋势，按日历期对齐
现金及短期投资MEDPRBLX
| Q4 25 | $497.0M | $3.1B | ||
| Q3 25 | $285.4M | $2.9B | ||
| Q2 25 | $46.3M | $2.6B | ||
| Q1 25 | $441.4M | $2.7B | ||
| Q4 24 | $669.4M | $2.4B | ||
| Q3 24 | $656.9M | $2.3B | ||
| Q2 24 | $510.9M | $2.4B | ||
| Q1 24 | $407.0M | $2.4B |
总债务MEDPRBLX
| Q4 25 | — | $1.2B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益MEDPRBLX
| Q4 25 | $459.1M | $394.5M | ||
| Q3 25 | $293.6M | $407.6M | ||
| Q2 25 | $172.4M | $353.2M | ||
| Q1 25 | $593.6M | $310.7M | ||
| Q4 24 | $825.5M | $221.4M | ||
| Q3 24 | $881.4M | $189.9M | ||
| Q2 24 | $763.6M | $121.5M | ||
| Q1 24 | $671.5M | $71.6M |
总资产MEDPRBLX
| Q4 25 | $2.0B | $9.6B | ||
| Q3 25 | $1.8B | $8.6B | ||
| Q2 25 | $1.6B | $7.8B | ||
| Q1 25 | $1.9B | $7.5B | ||
| Q4 24 | $2.1B | $7.2B | ||
| Q3 24 | $2.1B | $6.7B | ||
| Q2 24 | $1.9B | $6.5B | ||
| Q1 24 | $1.8B | $6.3B |
负债/权益比MEDPRBLX
| Q4 25 | — | 2.98× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 5.48× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $192.7M | $607.0M |
| 自由现金流经营现金流 - 资本支出 | $188.1M | $308.6M |
| 自由现金流率自由现金流/营收 | 26.6% | 21.8% |
| 资本支出强度资本支出/营收 | 0.6% | 21.1% |
| 现金转化率经营现金流/净利润 | 1.43× | — |
| 过去12个月自由现金流最近4个季度 | $681.9M | $1.4B |
8季度趋势，按日历期对齐
经营现金流MEDPRBLX
| Q4 25 | $192.7M | $607.0M | ||
| Q3 25 | $246.2M | $546.2M | ||
| Q2 25 | $148.5M | $199.3M | ||
| Q1 25 | $125.8M | $443.9M | ||
| Q4 24 | $190.7M | $184.5M | ||
| Q3 24 | $149.1M | $247.4M | ||
| Q2 24 | $116.4M | $151.4M | ||
| Q1 24 | $152.7M | $238.9M |
自由现金流MEDPRBLX
| Q4 25 | $188.1M | $308.6M | ||
| Q3 25 | $235.5M | $443.6M | ||
| Q2 25 | $142.4M | $176.7M | ||
| Q1 25 | $115.8M | $426.5M | ||
| Q4 24 | $183.0M | $120.6M | ||
| Q3 24 | $138.5M | $218.0M | ||
| Q2 24 | $103.5M | $111.7M | ||
| Q1 24 | $147.2M | $192.3M |
自由现金流率MEDPRBLX
| Q4 25 | 26.6% | 21.8% | ||
| Q3 25 | 35.7% | 32.6% | ||
| Q2 25 | 23.6% | 16.3% | ||
| Q1 25 | 20.7% | 41.2% | ||
| Q4 24 | 34.1% | 12.2% | ||
| Q3 24 | 26.0% | 23.7% | ||
| Q2 24 | 19.6% | 12.5% | ||
| Q1 24 | 28.8% | 24.0% |
资本支出强度MEDPRBLX
| Q4 25 | 0.6% | 21.1% | ||
| Q3 25 | 1.6% | 7.5% | ||
| Q2 25 | 1.0% | 2.1% | ||
| Q1 25 | 1.8% | 1.7% | ||
| Q4 24 | 1.4% | 6.5% | ||
| Q3 24 | 2.0% | 3.2% | ||
| Q2 24 | 2.4% | 4.4% | ||
| Q1 24 | 1.1% | 5.8% |
现金转化率MEDPRBLX
| Q4 25 | 1.43× | — | ||
| Q3 25 | 2.22× | — | ||
| Q2 25 | 1.65× | — | ||
| Q1 25 | 1.10× | — | ||
| Q4 24 | 1.63× | — | ||
| Q3 24 | 1.55× | — | ||
| Q2 24 | 1.32× | — | ||
| Q1 24 | 1.49× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
RBLX
暂无分部数据
